Kevin Kabler is a partner in Goodwin’s nationally recognized Life Sciences group. His practice focuses on developing and implementing value-creating patent portfolio strategies for emerging and mature life sciences companies. Dr. Kabler integrates with his clients, fully understands their business goals, and works directly with them to build comprehensive and efficient patent portfolio strategies to advance those goals.
Dr. Kabler’s practice also involves strategic patent counseling and intellectual property due diligence for his life sciences clients, including companies and investors. His diligence work includes acting as lead patent counsel on behalf of his clients in mergers, acquisitions, and strategic partnership formation with pharmaceutical and biotechnology companies. He has extensive experience advising his clients in assessing competitive landscapes, complex intellectual property assets, associated risks, and thoughtful mitigation of those risks. His deep diligence experience and strategic insights have made him one of the most preferred diligence counsel in California for life sciences companies and their investors.
Representative Matters
- Kyverna Therapeutics on its $366 million initial public offering
- Absci on its $200 million initial public offering
- Senti Biosciences on its business combination with Dynamics Special Purpose Corp. to create Senti Biosciences, Inc.
- Axcella Health on its $71 million initial public offering
- Connect Biopharma on its $219 million initial public offering
- Zymeworks on its $115 million initial public offering
- Gritstone bio on its initial public offering* and follow-on public offerings
- ArsenalBio on its $220 million Series B financing
- ArsenalBio on its $86 million Series A financing
- Kyverna Therapeutics on its $145 million Series B financing
- HI-Bio on its $95 million Series B financing
- Connect Biopharma on its $115 million Series C financing
- Octave Bioscience on its $32 million Series B financing
- Octave Bioscience on its $30 million Series B financing extension
- TRexBio on its $85 million Series A financing
- Cartography Biosciences on its $57 million Series A financing
- Arrowmark Partners and RA Capital on their $42.5 million Series E investment in Adagio Medical
- Senti Biosciences on its $105 million Series B financing
- Forty Seven on its $4.9 billion acquisition by Gilead
- ArsenalBio on its $70 million collaboration with Bristol Myers Squibb
- Pionyr Immunotherapeutics on its all-stock acquisition by Ikena Oncology
- Pionyr Immunotherapeutics on its $275 million exclusive option to Gilead
- Iconic Therapeutics on its exclusive option and license agreement with Exelixis to advance an innovative next-generation antibody-drug conjugate (ADC) program
- Iconic Therapeutics on its acquisition by Endpoint Health
- bit.bio on its collaboration and option agreement with BlueRock Therapeutics for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics
- HI-Bio on its equity participation and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)
- Blackstone Life Sciences on its joint investment alongside Ferring Pharmaceuticals of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late-stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC)
- Gritstone bio on its collaboration with bluebird bio
Professional Experience
Prior to joining Goodwin in 2019, Dr. Kabler was a partner at Fenwick & West LLP. Before joining Fenwick & West, he was a post-doctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.
Credentials
Education
JD
University of California College of the Law, San Francisco
(magna cum laude, Order of the Coif, Thurston Honor Society)
PhDImmunology
Baylor College of Medicine
BSMicrobiology
Kansas State University
(cum laude)
Admissions
Bars
- California
- U.S. Patent and Trademark Office (USPTO)